title: Increasing levels of dietary homocystine with carotid endarterectomy produced proportionate increases in plasma homocysteine and intimal hyperplasia.
abstract: OBJECTIVE
  The role that homocysteine may play in post-carotid endarterectomy (CEA) restenosis due to intimal hyperplasia is not well understood. This study was designed to investigate the effects of different levels of dietary homocystine on: (1) plasma homocysteine; (2) post-CEA intimal hyperplasia; and (3) levels of the methyl donor S-adenosylmethionine (SAM) and its counterpart S-adenosylhomocysteine (SAH) in the homocysteine pathway.
  
  
  METHODS
  Male rats were fed specialized diets for 2 weeks pre- and post-CEA. Groups included control (0 homocystine added, n=9), 1.5 (1.5 g/kg homocystine added, n=10), 3.0 (3.0 g/kg homocystine added, n=9), and 4.5 (4.5 g/kg homocystine added, n=11). The rats underwent a surgical carotid endarterectomy. Endpoints included; plasma homocysteine, intimal hyperplasia, replicative index using with alpha-SM actin and BrdU, hepatic SAM levels, SAH levels, and the hepatic activities of methylenetetrahydrofolate reductase (MTHFR) and cystathionine beta-synthase (CBS).
  
  
  RESULTS
  Increasing dietary homocystine produced a proportionate increase in plasma homocysteine and an increase in intimal hyperplasia. Regression analysis of plasma homocysteine levels and intimal hyperplasia showed a significant correlation (r=0.71,P=0.003). Plasma homocysteine levels above 15 microM were associated with significant increases in intimal hyperplasia above 6.5% (P=0.04). Elevation of plasma homocysteine levels to moderate levels (5-25 microM) resulted in significant post-CEA intimal hyperplasia. Cellular analysis of the area of intimal hyperplasia in all diet groups showed comparable amounts of cells positive for alpha-SM actin. However, with increasing levels of dietary homocystine and plasma homocysteine there was an increase in replicative index (P<0.001) as determined by BrdU staining. Increasing dietary homocystine increased plasma homocysteine and was followed by increases in the replicative index thus producing increased intimal hyperplasia and lumenal stenosis. In hepatic measurements the 1.5 and 3.0 g/kg homocystine diets caused: increased liver activity of MTHFR (P=0.03) and decreased hepatic levels of SAM, SAH and SAM/SAH ratios compared to controls. Homocystine treatment did not cause significant alterations in CBS levels (P=0.992). These studies also showed no correlation of the MTHFR and CBS enzymes with plasma homocysteine levels or intimal hyperplasia. However, hepatic levels of SAM showed significant negative correlations with plasma homocysteine (r=-0.58; P=0.006) and with BrdU percentages of cellular proliferation (r=-0.69; P=0.06).
  
  
  CONCLUSIONS
  The degree of post-CEA intimal hyperplasia in a rat model is directly related to the plasma level of homocysteine. The hyperplastic effects of homocysteine may be mediated in part by a physiological insufficiency of methyl donors as shown by decreases in SAM. Thus, increasing levels of plasma homocysteine enhanced and accelerated the smooth muscle cell response after CEA which led to increased intimal hyperplasia and lumenal stenosis.
authors.affiliation: Department of Surgery, Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, USA.
authors.forename: F
authors.initials: F
authors.lastname: Southern
authors.forename: J
authors.initials: J
authors.lastname: Eidt
authors.forename: J
authors.initials: J
authors.lastname: Drouilhet
authors.forename: P
authors.initials: P
authors.lastname: Mukunyadzi
authors.forename: D K
authors.initials: DK
authors.lastname: Williams
authors.forename: C
authors.initials: C
authors.lastname: Cruz
authors.forename: Y F
authors.initials: YF
authors.lastname: Wang
authors.forename: L A
authors.initials: LA
authors.lastname: Poirier
authors.forename: A T
authors.initials: AT
authors.lastname: Brown
authors.forename: M M
authors.initials: MM
authors.lastname: Moursi
mesh_terms: D000818:Animals; D002339:Carotid Arteries / Q000473:pathology*; D003541:Cystathionine beta-Synthase / Q000378:metabolism; D016894:Endarterectomy, Carotid; D006710:Homocysteine / Q000097:blood*; D006711:Homocystine / Q000008:administration & dosage*; D006965:Hyperplasia; D008099:Liver / Q000201:enzymology; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012008:Recurrence; D012435:S-Adenosylhomocysteine / Q000378:metabolism; D012436:S-Adenosylmethionine / Q000378:metabolism; D017539:Tunica Intima / Q000473:pathology*
chemical_list: D006710:Homocysteine; D006711:Homocystine; D012436:S-Adenosylmethionine; D012435:S-Adenosylhomocysteine; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D003541:Cystathionine beta-Synthase